# Adhesion and Safety of Rotigexole Compared to Neupro®

> **NCT07015346** · NA · NOT_YET_RECRUITING · sponsor: **Eva Pharma** · enrollment: 40 (estimated)

## Conditions studied

- Idiopathic Parkinson Disease

## Interventions

- **DRUG:** Rotigexole 8 mg
- **DRUG:** Neupro ® 8 mg

## Key facts

- **NCT ID:** NCT07015346
- **Lead sponsor:** Eva Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2025-10-15
- **Final completion:** 2025-10-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07015346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07015346, "Adhesion and Safety of Rotigexole Compared to Neupro®". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07015346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*